Does Novo Nordisk’s slimmed down rebrand signal a new era of DTC revivalism?
Novo Nordisk, the Dandish drugmaker behind the weight-loss drugs Ozempic and Wegovy, announced it’s rebranding to “Novo” beginning this week. It’s part of a larger trend in healthcare branding. The rise of telehealth, direct-to-consumer pharmaceutical companies, and consu
<p>Novo Nordisk, the Dandish drugmaker behind the weight-loss drugs Ozempic and Wegovy, announced it’s rebranding to “Novo” beginning this week.
It’s part of a larger trend in healthcare branding. The rise of telehealth, direct-to-consumer pharmaceutical companies, and consu</p>